Search results
Abstract. Expansion of extracellular fluid volume is central to the pathophysiology of heart failure. Increased extracellular fluid leads to elevated intracardiac filling pressures, resulting in a constellation of signs and symptoms of heart failure referred to as congestion.
1 kwi 2022 · The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients’ interests.
8 lis 2023 · Evaluation and optimization of volume status is an essential component of treatment in patients with systolic or diastolic heart failure (HF) . Removal of excess extracellular fluid with diuretics to treat peripheral and/or pulmonary edema is one of the mainstays of volume management.
27 sie 2021 · This document is for patients with heart failure and their caregivers and is based on the longer European Society of Cardiology (ESC) Clinical Practice Guidelines for the diagnosis and treatment of acute and chronic heart failure.
26 lip 2021 · This Perspective discusses the major clinical trials of intravenous iron supplementation in patients with HFrEF, addresses potential safety concerns of intravenous iron, provides new insights on oral iron repletion, and proposes future directions.
1 kwi 2022 · The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients’ interests.
9 mar 2020 · For patients not receiving long-term loop diuretic agents, 40-80 mg IV BID of furosemide or the equivalent is a reasonable, empiric, starting dose. Due to post-dosing Na + retention, IV loop-diuretic agents should usually be given at least twice daily.
